May 6 |
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
|
Apr 17 |
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
|
Apr 10 |
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
|
Apr 1 |
BioLineRx to raise $6M through a direct offering
|
Apr 1 |
BioLineRx Announces $6 Million Registered Direct Offering
|
Mar 27 |
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
|
Mar 27 |
BLRX: First Aphexda Sales Recognized
|
Mar 26 |
BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript
|
Mar 26 |
BioLineRx GAAP EPS of -$0.06, revenue of $4.8M
|
Mar 26 |
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
|